Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535112) titled 'A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation' on April 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bayer
Condition:
Advanced/Metastatic Colorectal Adenocarcinoma
Intervention:
Drug: BAY 3771249
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 15, 2026
Target Sample Size: 130
Countries of Recruitment:
United States
Australia
B...